Skip to main content
Kent Academic Repository

Posterior Reversible Encephalopathy Syndrome after Pazopanib Therapy

Savaliya, Madhavkumar, Surati, Drishty, Surati, Ramesh, Padmani, Shailesh, Boussios, Stergios (2023) Posterior Reversible Encephalopathy Syndrome after Pazopanib Therapy. Diseases, 11 (2). Article Number 76. E-ISSN 2079-9721. (doi:10.3390/diseases11020076) (KAR id:101572)


The term posterior reversible encephalopathy syndrome (PRES) refers to an acute syndrome characterised by a range of neurological symptoms and posterior transient changes on neuroimaging. Common clinical presentation includes headache, confusion, visual disturbances, seizures, and focal neurological deficit. With the advancement and increasing availability of neuroimaging, this syndrome is increasingly recognised. There are several underlying causes for PRES, including certain medications. Tyrosine kinase inhibitors (TKIs) such as pazopanib can increase the risk of developing PRES by markedly elevating the blood pressure due to its effect of inhibition of vascular endothelial growth factor receptors (VEGFRs). We are reporting a case of a 55-year-old male patient with the clear cell type of renal cell carcinoma (RCC) who developed PRES within a short period after starting pazopanib therapy. With the effective control of his blood pressure and discontinuation of pazopanib, his typical magnetic resonance imaging (MRI) lesion of PRES resolved in the follow-up scan after four weeks.

Item Type: Article
DOI/Identification number: 10.3390/diseases11020076
Uncontrolled keywords: renal cell cancer, tyrosine kinase inhibitors, pazopanib, posterior reversible encephalopathy syndrome
Subjects: R Medicine
Divisions: Divisions > Division of Natural Sciences > Kent and Medway Medical School
Funders: University of Kent (
SWORD Depositor: JISC Publications Router
Depositing User: JISC Publications Router
Date Deposited: 08 Jun 2023 09:20 UTC
Last Modified: 09 Jun 2023 07:56 UTC
Resource URI: (The current URI for this page, for reference purposes)

University of Kent Author Information

  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.